Aradigm granted continued Nasdaq listing

3 September 2006

USA-based Aradigm Corp has been granted its request for continued listing on the US Nasdaq Capital Market, following a hearing before the Nasdaq's Listing Qualifications Panel in which the company outlined its near-term strategies for achieving and maintaining compliance noting in particular the effect of its shareholders' equity on the company's non-dilutive transaction with Novo Nordisk that was announced in early July.

Aradigm combines its advanced AERx pulmonary delivery platform and novel formulations to create products that enable patients to comfortably self-administer biopharmaceuticals and small-molecule drugs. The firm's AERx insulin Diabetes Management System (iDMS) has been licensed to Novo Nordisk for development and commercialization in return for royalties, and is in Phase III testing for type 1 and type 2 diabetes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.